Pharmaceutical Pricing and Reimbursement in Japan: For Faster, More Complete Access to New Drugs

Conclusions:
From the view of NHI coverage scope and speed, the hurdle to access new drugs in Japan is shown to be lower than in other countries that also set public prices for reimbursement. Although the difficulty of controlling health expenditures increases, drug pricing that properly reflects the drug’s clinical value is important in that it also furthers the development of medical technology. Better price setting can also facilitate patient access to innovative drugs.

Source: Therapeutic Innovation and Regulatory Science - April 20, 2016 Category: Drugs & Pharmacology Authors: Takayama, A., Narukawa, M. Tags: Global Perspectives Source Type: research